Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

22 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Companies

Top Ten Companies // Browse A - Z of companies

  • Merck KGaA (Merck)
  • Merck (Merck KGaA)
  • Pfizer
  • Roche
  • Novartis
  • GlaxoSmithKline (GSK)
  • GSK (GlaxoSmithKline)
  • Bristol-Myers Squibb
  • Lilly
  • Bayer

Browse the A - Z of Companies

  • #
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

O

  • Obagi Medical Products
  • Oceana Therapeutics
  • Octapharma
  • OctoPlus
  • Oculus Innovative Sciences
  • Ohara Pharmaceutical
  • Olainfarm
  • Olden Group
  • OLIC
  • Omega Pharma
  • Omnivest
  • Onco Therapies
  • Oncodesign
  • OncoGenex
  • Oncolys BioPharma
  • OncoMed Pharmaceuticals
  • Onconova Therapeutics
  • Oncopeptides
  • OncoProd
  • Oncothyreon
  • Only for Children Pharmaceuticals
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals
  • Onyx Scientific
  • Opexa Therapeutics
  • Ophthotech
  • OPKO Health
  • Optimer Biotechnology
  • Optimer Pharmaceuticals
  • Opus Group
  • OraPharma
  • Orchid Chemicals & Pharmaceuticals
  • Orchid Healthcare
  • Orexa
  • Orexigen Therapeutics
  • Orexo AB
  • Organon
  • OriGene Technologies
  • Orion Corp
  • Orion Laboratories
  • Orion Pharma
  • Orphan Therapeutics
  • Orphazyme
  • Ortho Centocor
  • Ortho-McNeil
  • Ortho-McNeil-Janssen
  • OSI Pharmaceuticals
  • Osiris Therapeutics
  • Ossianix
  • Osteologix
  • Osteotech
  • Osteros Biomedica
  • Othera Pharmaceuticals
  • Otsuka
  • OvaMed
  • Owen Mumford
  • Oxford BioMedica
  • Oxford BioTherapeutics
  • Oxford Cancer Biomarkers
  • OXiGENE
  • Hot Topics
  • Most Read
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
  • Is failure to adopt business process management putting the pharma industry at risk?
  • Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
  • New Zealand declines Alexion's funding application for Solaris
  • AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
  • Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS